Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 2, 2017, Pages

  Horita, Nobuyuki ^a   Goto, Atsushi ^b   Shibata, Yuji ^a   Ota, Erika ^c   Nakashima, Kentaro ^a   Nagai, Kenjiro ^a   Kaneko, Takeshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c ST LUKE'S INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;

CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; CAUSE OF DEATH; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; MUSCARINIC ANTAGONISTS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85012097955     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012066.pub2     Document Type: Review

References (66)

1. Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler (ENERGITO study). International Journal of Chronic Obstructive Pulmonary Disease 2016;11:193-205. [4898683; PUBMED: 26893551]
2. Donohue J, Worsley S, Zhu CQ, Hardaker L, Church A. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest 2014;146(4):73A. [4898685]
3. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine 2015;109(7):870-81. [4898686; PUBMED: 26006754]
4. Donohue J, Worsley S, Zhu CQ, Hardaker L, Church A. Efficacy and safety of umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. Chest 2014;146(4):73A. [4898688]
5. Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine 2015;109(7):870-81. [4898689; PUBMED: 26006754]
6. Hoshino M, Ohtawa J, Akitsu K. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair((R)) in chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 2015;30:128-33. [4898691; PUBMED: 25183687]
7. Magnussen H, Maltais F, Schmidt H, Kesten S, Metzdorf N. Comparison of tiotropium+salmeterol vs. fluticasone+salmeterol on lung volumes, exercise tolerance and locus of symptom limitation. American Journal of Respiratory and Critical Care Medicine 2010;181:A4472. [4898693]
8. Magnussen H, Paggiaro P, Schmidt H, Kesten S, Metzdorf N, Maltais F. Effect of combination treatment on lung volumes and exercise endurance time in COPD. Respiratory Medicine 2012;106(10):1413-20. [4898694; PUBMED: 22749044]
9. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008;134(2):255-62. [4898696; PUBMED: 18403672]
10. Rabe KF, Timmer W, Sagriotis A, Viel K. Comparison of a combination of tiotropium and formoterol to salmeterol and fluticasone in moderate COPD. 15th European Respiratory Society Annual Congress; 2005 Sept 30-31; Copenhagen, Denmark. 2005. [4898697]
11. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations. European Respiratory Journal 2014;44(Suppl 58):P290. [4898699]
12. Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulmonary Medicine 2015;15:91. [4898700; PUBMED: 26286141]
13. Bateman E, Vogelmeier C, Chen H, Banerji D. Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. American College of Chest Physicians 2014;145(3):409A. [4898702]
14. Bateman ED, Vogelmeier C, Pallante J, Bryant H, Alagappan V, D'Andrea P, et al. Once-daily QVA149 demonstrates superior lung function compared to twice-daily salmeterol/fluticasone in all subgroups of COPD patients: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine 2013;187:A4273. [4898703]
15. Bateman ED, Vogelmeier C, Pallante J, Bryant H, Alagappan V, D'Andrea P, et al. Once-daily QVA149 improves breathlessness and reduces rescue medication use compared to twice-daily salmeterol/fluticasone in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine 2013;187:A2433. [4898704]
16. Mezzi K, Pallante J, Alagappan V, Chen H, Banerji D. Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting β2-agonist/inhaled corticosteroid (LABA/ICS): the ILLUMINATE study. Chest 2014;145(3):424A. [4898705]
17. Vogelmeier C, Bateman E, Pallante J, Bryant H, Alagappan VD, Andrea P, et al. Once-daily QVA149 provides superior bronchodilation and improves lung function versus twice-daily fluticasone/salmeterol in COPD patients: the ILLUMINATE study. British Thoracic Society Winter Meeting 2012;67:A149, P194. [4898706]
18. Vogelmeier C, Bateman ED, Pallante J, Bryant H, Alagappan V, D'Andrea, et al. QVA149 once daily is safe and well tolerated in patients with COPD: the ILLUMINATE study. American Journal of Respiratory and Critical Care Medicine 2013;187:A1477. [4898707]
19. Vogelmeier CD, Bateman ED, D'Andrea P, Mezzi K, Chen H, Banerji D, et al. Once-daily QVA149 is more effective than twice-daily salmeterol/fluticasone in improving lung function, in patients with severe chronic obstructive pulmonary disease (COPD): the illuminate study. American Journal of Respiratory and Critical Care Medicine 2014;189:A3763. [4898708]
20. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet. Respiratory Medicine 2013;1(1):51-60. [4898709; PUBMED: 24321804]
21. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten A, et al. The efficacy and safety of aclidinium/formoterol fixed-dose combination compared with salmeterol/fluticasone in patients with COPD: results from a phase III study. American Journal of Respiratory and Critical Care Medicine 2015;191:A3974. [4898711]
22. Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal 2016; Vol. 48, issue 4:1030-9. [4898712]
23. Kwaijtaal M, Wedzicha J, Decramer M, Vestbo J, Banerji D. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Respirology 2014:TP177. [4898714]
24. Wedzicha J, Vestbo J, Gallagher N, Banerji D. A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: the FLAME study. Chest 2014;145(3):408A. [4898715]
25. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. New England Journal of Medicine 2016;374(23):2222-34. [4898716; PUBMED: 27181606]
26. Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:1015-26. [4898718]
27. Bruhn C. Chronic obstructive pulmonary disease: recommendation of salmeterol in fixed combination. Deutsche Apotheker-Zeitung 2003;143(11):48-51. [4898720]
28. Calverley P, Stockley R, Seemungal T, Hagan G, Wedzicha J. Adverse events and mortality in the INSPIRE study (Investigating New Standards for Prophylaxis In Reduction of Exacerbations). 17th European Respiratory Society Annual Congress 2007;30:125s [P847]. [4898722]
29. Knobil K, Kalberg C, Merchant K, Emmett A, Cicale M. Maintenance of bronchodilator response for Advair Diskus 250/50 (fluticasone propionate/salmeterol) but not ipratropium/albuterol in patients with COPD. Chest 2004;126(Suppl 4):807S. [4898724]
30. Knobil K, Merchant K, Kalberg C, Emmett A, Cicale M. A comparison of patient perceived improvement in symptoms after initiating therapy with either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or ipratropium/albuterol. Chest 2004;126(Suppl 4):806S-b-807S-b. [4898726]
31. NCT00120978 . Can advair and flovent reduce systemic inflammation related to chronic obstructive pulmonary disease (COPD)? A multi-center randomized controlled trial. clinicaltrials.gov/ct2/show/NCT00120978 Date first received: 11 July 2005. [4898728]
32. Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respiratory Medicine 2014;108(12):1786-93. [4898730]
33. Sciurba FC, Kalberg C, Emmett A, Merchant K, Brown C, Knobil K. Efficacy of Advair Diskus 250/50 (fluticasone propionate/salmeterol) or ipratropium/albuterol in patients with COPD associated with chronic bronchitis and/or emphysema. Chest 2004;126(Suppl 4):807S-a-808S-a. [4898732]
34. NCT02497001 . A randomized, double-blind, parallel-group, 24-week, chronic-dosing, multi-center study to assess the efficacy and safety of PT010, PT003, and PT009 compared with Symbicort® Turbuhaler® (Kronos). clinicaltrials.gov/show/NCT02497001 Date first received: 8 July 2015. [4898734]
35. NCT02516592 . Assessment of switching from salmeterol/fluticasone to indacaterol/glycopyrronium in a symptomatic COPD patient cohort (FLASH). Date first received: 4 August 2015. [4898736]
36. Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease 2014;5(2):85-98.
37. Anderson R, Theron AJ, Steel HC, Durandt C, Tintinger GR, Feldman C. The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro. Mediators of Inflammation 2014;2014:105420.
38. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80(2):89-95.
39. Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966;1(7442):830-5.
40. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg C, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 2014;145(5):981-91.
41. Cluzeau F, Wedzicha JA, Kelson M, Corn J, Kunz R, Walsh J, et al. Stakeholder involvement: how to do it right: article 9 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proceedings of the American Thoracic Society Journal 2012;9(5):269-73.
42. Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Family Practice 2014;15:42.
43. Frampton JE. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs 2014;74(4):465-88.
44. The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 16 August 2016).
45. The Global Initiative for Chronic Obstructive Lung Disease. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. www.goldcopd.org/Guidelines/guidelines-resources.html (accessed 7 December 2016).
46. Brozek J, Oxman A, Schünemann H. GRADEpro. Version 3.2 for Windows. Hamilton (ON): McMaster University, 2008.
47. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
48. Hanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulmonary Pharmacology & Therapeutics 2008;21(3):540-50.
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
50. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
51. Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. International Journal of Chronic Obstructive Pulmonary Disease 2015;10:813-22.
52. Horita N, Miyazawa N, Tomaru K, Inoue M, Kaneko T. Long-acting muscarinic antagonist+long-acting beta agonist versus long-acting beta agonist+inhaled corticosteroid for COPD: a systematic review and meta-analysis. Respirology 2015;20(8):1153-9.
53. Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD - role of umeclidinium/vilanterol. International Journal of Chronic Obstructive Pulmonary Disease 2014;9:687-95.
54. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
55. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2]
56. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4]
57. Oba Y, Chandran AV, Devasahayam JV. Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting β-agonist for COPD: a meta-analysis. COPD 2016;13(6):677-85.
58. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respiratory Medicine 2015;3(6):435-42.
59. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal of Respiratory and Critical Care Medicine 2001;163(5):1256-76.
60. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
61. Schachter EN. Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barcelona, Spain: 1998) 2013;49(7):437-46.
62. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. European Respiratory Journal 2009;34(1):13-6.
63. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125(1):249-59.
64. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PLoS One 2013;8(10):e75221.
65. World Health Organization. Chronic respiratory disease: chronic obstructive pulmonary disease (COPD): burden of COPD. www.who.int/respiratory/copd/burden/en/ (accessed 31 October 2015).
66. Horita N, Goto A, Ota E, Nakashima K, Nagai K, Kaneko T. Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD012066]